Jounce Therapeutics, Inc. Common Stock
JNCE
JNCE was delisted on the 3rd of May, 2023.
104 hedge funds and large institutions have $194M invested in Jounce Therapeutics, Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 25 increasing their positions, 41 reducing their positions, and 15 closing their positions.
13% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 15
2% more funds holding
Funds holding: 102 → 104 (+2)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
6% less capital invested
Capital invested by funds: $207M → $194M (-$13.3M)
26% less call options, than puts
Call options by funds: $1.06M | Put options by funds: $1.44M
39% less repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 41
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$13.2M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$10.7M |
| 3 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$7.2M |
| 4 |
BlackRock
New York
|
+$2.62M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$817K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TGI
TRV GP II
Boston,
Massachusetts
|
-$8.02M |
| 2 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$2.88M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$2.35M |
| 4 |
Renaissance Technologies
New York
|
-$1.32M |
| 5 |
Russell Investments Group
London,
United Kingdom
|
-$901K |
JNCE Hedge Fund Activity: Q4 2020 in Review
104 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Jounce Therapeutics, Inc. Common Stock (JNCE) for Q4 2020, worth a combined $194M — down 6.4% from $207M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new JNCE positions and 15 closed out — a net gain of 2 holders — while 25 added to existing stakes and 41 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $13.2M. The largest seller was TRV GP II, cutting an estimated $8.02M.
- 104 institutional investors held Jounce Therapeutics, Inc. Common Stock (JNCE) as of Q4 2020, up from 102 in Q3 2020.
- Funds reported $194M of Jounce Therapeutics, Inc. Common Stock stock for Q4 2020, down 6.4% quarter-over-quarter.
- 17 funds opened new Jounce Therapeutics, Inc. Common Stock positions in Q4 2020 and 15 closed out, a net change of +2 holders.
- The largest Jounce Therapeutics, Inc. Common Stock buyer in Q4 2020 was Citadel Advisors, an estimated $13.2M added.
- The largest Jounce Therapeutics, Inc. Common Stock seller in Q4 2020 was TRV GP II, an estimated $8.02M sold.
Based on aggregated 13F filings for Q4 2020.